Elevar Therapeutics

About:

Elevar Therapeutics specializes in clinical development of promising therapies for unmet medical needs in cancer.

Website: https://elevartherapeutics.com

Description:

LSK BioPartners, Inc (dba LSK BioPharma) is a privately-held pharmaceutical company based in Salt Lake City, Utah with offices in South San Francisco (and Pangyo, South Korea). LSK BioPharma (LSKB) specializes in clinical development of promising therapies for unmet medical needs in cancer. LSKB is developing two proprietary drug candidates; rivoceranib (Apatinib), a VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors and a BTK/JAK3 inhibitor with the potential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent. LSKB holds worldwide rights for rivoceranib excluding China and has partnered for development and marketing in South Korea.

Total Funding Amount:

$20M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Salt Lake City, Utah, United States

Founded Date:

2005-01-01

Founders:

Sung Chul Kim

Number of Employees:

101-250

Last Funding Date:

2018-07-25

IPO Status:

Private

Industries:

© 2025 bioDAO.ai